Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS receives R10 million in student funding from Absa
2017-06-19

 

Description: UFS receives R10 million in student funding from Absa Tags: UFS receives R10 million in student funding from Absa

From the left: Asive Dlanjwa (UFS SRC) Prof Francis Petersen, Fikemini Dlamini,
Bertie Smith and Lesley Afrika (student beneficiary 2016-2017)

 

In support of building a more equitable and prosperous Africa, and in response to the plight of students who lack financial aid at universities across the country, Absa Bank handed over a cheque of R10 million to the University of the Free State (UFS) at a ceremony held on the Bloemfontein Campus on 13 June 2017 by the office of Institutional Advancement. The allocation of these funds will assist students who meet the bursary programme criteria (proven financial need, students who are from households with a combined income of less than R1 million per annum, with an academic average of 55% or higher).

Corporate and higher education collaborate
Speaking at the event, Rector and Vice-Chancellor of the UFS Prof Francis Petersen highlighted the important role corporates play in collaborating with educational institutions to help support future professionals who are the future builders of the economy and will later lead industry. “Absa and the UFS enjoy a good relationship and it is our hope that this bursary programme will grow from strength to strength,” he said.

In 2016 alone, Absa Bank disbursed R12 million towards settling outstanding fees for 439 students in four faculties of the UFS. In 2017 the funds will be allocated similarly to cover financial needs of qualifying students. Mr Bertie Smith, Absa Management Executive: Central Region said: “The university plays an important role in building future leaders and Absa’s strategy of shared growth supports the focus on education.”

Responding to a greater socioeconomic need
The event was attended by staff of the UFS and delegates from the Absa group, as well as students who were beneficiaries of the Absa Bursary Fund in 2016. Mr Fikemini Dlamini, Absa Head: Public Sector Business Banking, said the bursary programme was born out of the growing need to fund and develop the education of young people, and is a response to the outcry from students across the country in the “Fees Must Fall” movement. He said: “Educating one young person has a knock-on effect that has the potential to alleviate poverty in many families and communities around us.”



We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept